Artificial intelligence research in the COVend COVID-19 clinical trial project

Authors

• Alpo Olavi Värri Faculty of Medicine and Health Technology, Tampere University, Tampere http://orcid.org/0000-0002-3214-3458
• Antti Kallonen Faculty of Medicine and Health Technology, Tampere University, Tampere https://orcid.org/0000-0001-6199-6356
• Tunc Asuroglu Faculty of Medicine and Health Technology, Tampere University, Tampere https://orcid.org/0000-0003-4153-0764
• Mark van Gils Faculty of Medicine and Health Technology, Tampere University, Tampere https://orcid.org/0000-0002-0029-1771

DOI: https://doi.org/10.23996/fjhw.126881

Keywords:

COVID-19, artificial intelligence, FX06, intensive care

Abstract

The COVend project aims at delivering a new effective therapy, FX06, against the SARS-CoV-2 virus infection for the management of the COVID-19 disease in hospitals. Nine of the 17 partners of the project consortium are hospitals responsible for collecting study subjects and administering the FX06 therapy to the patients. Although the clinical trial (IXION) has the main role in the project, the project has also a work package which develops and applies artificial intelligence (AI) methods to the data collected during the 28-day study period from the patients receiving the therapy. The AI work package applies exploratory data analysis methods to find patterns and profiles of the patients. Combined with the data about treatment methods and patient outcomes, the aim is to provide decision support for the therapy intervention in the later stage of the project.